CoChat

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

The DOI matches its Crossref record; 20 of the 24 references it cites were found in a registry or an index.

Abstract

Objectives To determine whether baseline prostate-specific antigen (PSA), in addition to prostate volume, is associated with long-term changes in symptoms and urinary flow rate.Methods Three thousand forty men with benign prostatic hyperplasia enrolled in the PLESS trial were randomly assigned to finasteride 5 mg or placebo for 4 years. Symptoms and flow rate were assessed every 4 months, and data were analyzed by dividing the patients into three groups by baseline PSA tertiles (0 to 1.3, 1.4 to 3.2, and 3.3 ng/mL or greater) and baseline prostate volume tertiles (14 to 41, 42 to 57, and 58 to 1 50 mL).Results After the initial placebo effect, a slow deterioration in symptoms over time was observed in the placebo-treated men with a baseline PSA 1.4 ng/mL or greater. However, placebo-treated men in the lowest PSA tertile (less than 1.4 ng/mL) had sustained symptomatic improvement that was not seen in placebo-treated men in the higher tertiles (P<0.001). In all finasteride-treated groups, there was initial improvement followed by maintenance or continued symptom improvement over time (approximately 3 to 3.5 points by the end of 4 years). The differences in symptom score improvement between placebo and finasteride were marginal for men with baseline PSA levels less than 1.4 ng/mL (P = 0.128) but were highly significant for men with PSA levels 1.4 ng/mL or greater (P<0.001). Urinary flow rate results were similar to those observed for symptoms. Analysis of symptom and flow rate data by prostate volume tertiles in a 10% subset of men yielded similar results, namely a deterioration of symptoms and flow rate in the two higher tertiles treated with placebo (greater than 41 mL) and a sustained improvement in all three groups of finasteride-treated patients.Conclusions Baseline PSA and prostate volume are good predictors of long-term symptomatic and flow rate changes. Baseline PSA levels of 1.4 ng/mL or greater and enlarged prostate glands predict the best long-term response to finasteride compared with placebo.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(99)00232-0

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Research works printed but not linked: 2

  1. Barry, 1995, Measuring disease-specific health status in men with benign prostatic hyperplasia, Med Care, 33, AS145, AS155
  2. Boyle, 1997, Baseline serum PSA levels predict degree of symptom improvement following therapy of BPH with finasteride, J Urol, 157, 134A

Cited by

See all 235

Metadata

Authors
Roehrborn, C. G., Boyle, P., Bergner, D., Gray, T., Gittelman, M., Shown, T., Melman, A., Bracken, R. B., deVere White, R., Taylor, A., Wang, D., & Waldstreicher, J.
Affiliations
  • University of California, Davis (US)
  • European Institute of Oncology (IT)
  • Tampa Bay Medical Research (US)
  • Lovelace Medical Center (US)
  • South Florida Medical Research (US)
  • Montefiore Medical Center (US)
  • University of Cincinnati (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Roehrborn, Claus G.
Venue
Urology
Publisher
Elsevier BV
Published
1999-10
Volume
54
Issue
4
Pages
662-669
ISSN
0090-4295 (ISSN-L)
OpenAlex
W2148027243
Cited by
233
References
24
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 8 · 2018: 6 · 2017: 7 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 12 · 2012: 5
FWCI
11.51
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Urology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Keywords
prostate-specific antigen, prostate volume, benign prostatic hyperplasia, finasteride, urinary flow rate, lower urinary tract symptoms, predictors of treatment response, placebo effect, alpha-blockers
MeSH terms
Enzyme Inhibitors, Humans, Male, Middle Aged, Predictive Value of Tests, Prostate, Prostatic Neoplasms, Time Factors, Urodynamics, Prostate-Specific Antigen, Finasteride

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. https://app.cochat.ai/papers/10.1016/s0090-4295(99)00232-0
The paper
Roehrborn, C. G., Boyle, P., Bergner, D., Gray, T., Gittelman, M., Shown, T., Melman, A., Bracken, R. B., deVere White, R., Taylor, A., Wang, D., & Waldstreicher, J. (1999). Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology. https://doi.org/10.1016/s0090-4295(99)00232-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.